Exploring a new treatment target for advanced prostate cancer
Official title: Testing ATAD2 as a new therapeutic target for advanced prostate cancer
Funded at University of California Los Angeles · NIH-10902612 · Data updated 2026-11-12
This study is looking at a new way to treat advanced prostate cancer that doesn't respond to regular treatments by testing a special type of medicine that targets a protein called ATAD2, with the hope of finding better options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $562,551 |
| NIH project number | 1R01CA287669-01A1 |
| Project ID | NIH-10902612 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, especially those whose cancer has progressed to castration-resistant prostate cancer or neuroendocrine prostate cancer.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates the potential of ATAD2 as a therapeutic target for advanced prostate cancer, particularly in cases that have become resistant to standard treatments. The approach involves testing ATAD2 inhibitors in pre-clinical models to assess their effectiveness in slowing down or stopping tumor growth. By understanding how ATAD2 contributes to the progression of prostate cancer, the study aims to develop new treatment strategies that could improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer, particularly those with treatment-resistant forms of the disease.
How similar studies have gone: Previous studies have shown promising results with similar approaches targeting ATAD2 in cancer treatment, indicating potential for success in this area.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Stoyanova, Tanya I — University of California Los Angeles
- Study coordinator: Stoyanova, Tanya I
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.